Comparative acute toxicity of paroxetine and other antidepressants

Kelvin, A. S.; Håkansson, Stellan

doi:10.1111/j.1600-0447.1989.tb07165.x

Cited by 17 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By comparing the acute toxicity of compound 25 (no effect at concentrations below 10 mg/kg) with that of paroxetine, it is found that this compound has almost the same effects as this SSRI. It is reported that paroxetine LD50 values in rats are 27 mg/kg following intravenous administration and 374 mg/kg per os [49]. Giving 120 mg/kg per os paroxetine to rats leads to reduced body weight and decreased food consumption [50].…”

Section: Discussionmentioning

confidence: 99%

Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome

Soubhye

Aldib

Prévost

et al. 2014

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome

Soubhye

Aldib

Prévost

et al. 2014

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…The range of doses we chose began near that which altered taste thresholds in humans (;0.2 mg/kg, Heath et al 2006) and increased to that which has been shown in other paradigms to affect motivated behavior (3-10 mg/kg, Sokolowski and Seiden 1999;Brimberg et al 2007) without causing motor deficits (up to 12 mg/kg, Drapier et al 2007); the timing of drug administration was also based on these reports. Our dose range also encompassed the dose clinically used in humans (Kelvin and Hackansson 1989), which is relevant since taste disturbances are at times reported with depression and as a side effect of SSRI use (see Settle and Amsterdam 1991), although to our knowledge this is not specific to treatment with paroxetine. At higher doses, paroxetine has been shown to completely suppress behavior (15 mg/kg, Joel et al 2004;20 mg/kg, Sokolowski and Seiden 1999), and so exploring the effects of higher doses on taste-guided behavior in the briefaccess test would most likely not prove fruitful.…”

Section: Discussionmentioning

confidence: 99%

The Selective Serotonin Reuptake Inhibitor Paroxetine Does Not Alter Consummatory Concentration-Dependent Licking of Prototypical Taste Stimuli by Rats

Mathes¹,

Spector²

2011

Chemical Senses

View full text Add to dashboard Cite

Serotonin and the 5HT(1A) receptor are expressed in a subset of taste receptor cells, and the 5HT(3) receptor is expressed on afferent fibers innervating taste buds. Exogenous administration of the selective serotonin reuptake inhibitor, paroxetine, has been shown to increase taste sensitivity to stimuli described by humans as sweet and bitter. Serotonergic agonists also decrease food and fluid intake, and it is possible that modulations of serotonin may alter taste-based hedonic responsiveness; alternatively, or in combination, serotonin may interact with physiological state to impact ingestive behavior. In this study, the unconditioned licking of prototypical taste stimuli by rats in brief-access taste tests was assessed following paroxetine administration (0.3-10 mg/kg intraperitoneal). We also measured sucrose licking by rats in different deprivation states after paroxetine (5 mg/kg). In neither experiment did we find any evidence of an effect of paroxetine on licking relative to water to any of the taste stimuli in the brief-access test at doses that decreased food intake. However, in some conditions, paroxetine decreased trials initiated to tastants. Therefore, a systemic increase in serotonin via paroxetine administration can decrease appetitive behavior in brief-access tests but is insufficient to alter taste-guided consummatory behavior.

show abstract

“…These figures suggest that the older TCAs are more likely to prove fatal in overdose than most of the newer drugs. Although there are several sources of bias in these data, the figures correlate with clinical impressions of overdose toxicity and with animal studies of lethality of antidepressants (Molcho & Stanley, 1992;Kelvin & Hakansson, 1989). There is sufficient evidence to implicate several of the older tricyclic drugs in fatal toxicity of antidepressants.…”

Section: Fatal Toxicity From Antidepressant Overdosementioning

confidence: 91%

Toxicity of newer versus older antidepressants

Henry¹

1997

Adv. psychiatr. treat

View full text Add to dashboard Cite

Of all the controversies over the different medications used in psychiatry, there is probably least dispute about the effectiveness of antidepressants in controlling depressive illness. However, the choice of which antidepressant to use is bedevilled by the spectre of potential toxicity from adverse effects, interactions and overdose. The unwanted effects may vary from mild and tolerable to potentially lethal. At one time it was relatively easy to become familiar with the problems surrounding the original two main groups of antidepressants – the tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAOIs). Recent years have seen the introduction of a number of newer drugs, with a wide range of chemical structures and differing pharmacological activities. They also have a new spectrum of adverse effects and interactions. It is worth reviewing the major differences between old and new antidepressants, and to identify the areas in which clinical caution must be exercised in order to avoid pitfalls and maximise clinical benefit.

show abstract

Comparative acute toxicity of paroxetine and other antidepressants

Cited by 17 publications

References 3 publications

Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome

Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome

The Selective Serotonin Reuptake Inhibitor Paroxetine Does Not Alter Consummatory Concentration-Dependent Licking of Prototypical Taste Stimuli by Rats

Toxicity of newer versus older antidepressants

Contact Info

Product

Resources

About